Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

An investigation of fecal volatile organic metabolites in irritable bowel syndrome.

Ahmed I, Greenwood R, Costello Bde L, Ratcliffe NM, Probert CS.

PLoS One. 2013;8(3):e58204. doi: 10.1371/journal.pone.0058204. Epub 2013 Mar 13.

2.

Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D.

Gut. 2007 Dec;56(12):1706-13. Epub 2007 Aug 3.

3.

Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.

Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F.

Inflamm Bowel Dis. 2008 Jan;14(1):32-9.

PMID:
17924558
4.

Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.

Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R.

Inflamm Bowel Dis. 2007 Nov;13(11):1374-8.

PMID:
17577247
5.

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.

D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P.

Inflamm Bowel Dis. 2012 Dec;18(12):2218-24. doi: 10.1002/ibd.22917. Epub 2012 Feb 16.

PMID:
22344983
6.

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.

Sydora MJ, Sydora BC, Fedorak RN.

J Crohns Colitis. 2012 Mar;6(2):207-14. doi: 10.1016/j.crohns.2011.08.008. Epub 2011 Sep 7.

PMID:
22325175
7.

Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.

Am J Gastroenterol. 2008 Jan;103(1):162-9. Epub 2007 Oct 4.

PMID:
17916108
8.

Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.

Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H.

Clin Lab. 2005;51(3-4):117-26.

PMID:
15819166
9.

Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome.

Manolakis AC, Kapsoritakis AN, Georgoulias P, Tzavara C, Valotassiou V, Kapsoritaki A, Potamianos SP.

BMC Gastroenterol. 2010 Oct 14;10:118. doi: 10.1186/1471-230X-10-118.

10.

Relationship between fecal lactoferrin and inflammatory bowel disease.

Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ.

Scand J Gastroenterol. 2007 Dec;42(12):1440-4.

PMID:
17852860
11.

[Fecal calprotectin in differential diagnosis of irritable bowel syndrome].

Li XG, Lu YM, Gu F, Yang XL.

Beijing Da Xue Xue Bao. 2006 Jun 18;38(3):310-3. Chinese.

12.

Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.

von Stein P, Lofberg R, Kuznetsov NV, Gielen AW, Persson JO, Sundberg R, Hellstrom K, Eriksson A, Befrits R, Ost A, von Stein OD.

Gastroenterology. 2008 Jun;134(7):1869-81; quiz 2153-4. doi: 10.1053/j.gastro.2008.02.083. Epub 2008 Mar 2.

PMID:
18466904
13.

Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease.

Ahmed I, Greenwood R, Costello B, Ratcliffe N, Probert CS.

Aliment Pharmacol Ther. 2016 Mar;43(5):596-611. doi: 10.1111/apt.13522. Epub 2016 Jan 25.

PMID:
26806034
14.

Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome.

Le Gall G, Noor SO, Ridgway K, Scovell L, Jamieson C, Johnson IT, Colquhoun IJ, Kemsley EK, Narbad A.

J Proteome Res. 2011 Sep 2;10(9):4208-18. doi: 10.1021/pr2003598. Epub 2011 Aug 8.

PMID:
21761941
15.

Prodromal irritable bowel syndrome may be responsible for delays in diagnosis in patients presenting with unrecognized Crohn's disease and celiac disease, but not ulcerative colitis.

Barratt SM, Leeds JS, Robinson K, Lobo AJ, McAlindon ME, Sanders DS.

Dig Dis Sci. 2011 Nov;56(11):3270-5. doi: 10.1007/s10620-011-1783-y. Epub 2011 Jun 22.

PMID:
21695401
16.

Accuracy of four fecal assays in the diagnosis of colitis.

Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F.

Dis Colon Rectum. 2007 Oct;50(10):1697-706.

PMID:
17762964
17.

Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity.

Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, Potamianos SP.

J Gastroenterol. 2012 May;47(5):519-30. doi: 10.1007/s00535-011-0516-5. Epub 2011 Dec 27.

PMID:
22200942
18.

Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice.

Annaházi A, Gecse K, Dabek M, Ait-Belgnaoui A, Rosztóczy A, Róka R, Molnár T, Theodorou V, Wittmann T, Bueno L, Eutamene H.

Pain. 2009 Jul;144(1-2):209-17. doi: 10.1016/j.pain.2009.04.017. Epub 2009 May 17.

PMID:
19450926
19.

The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?

Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, McPhail C, Rogala L, Miller N, Bernstein CN.

Clin Gastroenterol Hepatol. 2006 May;4(5):614-20. Epub 2006 Apr 17.

PMID:
16630762
20.

Differentiating coeliac disease from irritable bowel syndrome by urinary volatile organic compound analysis--a pilot study.

Arasaradnam RP, Westenbrink E, McFarlane MJ, Harbord R, Chambers S, O'Connell N, Bailey C, Nwokolo CU, Bardhan KD, Savage R, Covington JA.

PLoS One. 2014 Oct 16;9(10):e107312. doi: 10.1371/journal.pone.0107312. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk